Brief: Actinium Pharmaceuticals Announces Research Collaboration With Columbia University
08/12/2022 13:42
Dec 8 (Reuters) - Actinium Pharmaceuticals Inc ATNM.A :
* ACTINIUM PHARMACEUTICALS, INC. ANNOUNCES RESEARCH
COLLABORATION
WITH COLUMBIA UNIVERSITY TO STUDY ACTIMAB-A IN AML PATIENTS
FOLLOWING TRANSPLANT OF ENGINEERED HEMATOPOIETIC STEM CELLS GENE
EDITED TO BE CD33 NEGATIVE
Source text for Eikon: ID:nPnbz8h5Ma
Further company coverage: ATNM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actinium Pharmaceuticals
See all newsBrief: Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Brief: ctinium’s Atnm-400 Shows Strong Efficacy in TNBC, Beats Therapy Resistance at SABCS
Brief: Actinium Pharmaceuticals Says ATNM-400 Shows Superior Efficacy To Xtandi In Prostate Cancer
Brief: Actinium Pharmaceuticals Announces ATNM-400 A Novel Non-PSMA Targeting First In Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Brief: Actinium Pharmaceuticals Announces Supply Agreement With Eckert & Ziegler For AC-225 Radioisotope To Support Comprehensive Development Activities